All In Biotech

Drug Trial Radar · NCT05282030

Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Renal Impairment Compared to Healthy Participants.

An Open-label, Multi-center Phase 1 Pharmacokinetic and Tolerability Study of Tolebrutinib Given as a Single Oral Dose in Participants With Renal Impairment and in Matched Participants With Normal Renal Function.

Last checked: Nov 20, 2026Latest source record: Feb 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

22

Actual

Start

Mar 10, 2022

Primary completion

Aug 2, 2022

Study completion Aug 2, 2022

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Mar 16, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 79 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this parallel group, Phase 1, open-label, 2-arm study is to assess the effect of severe (Part A) and moderate (Part B, conditional) renal impairment (RI) on pharmacokinetics (PK), safety and tolerability of tolebrutinib tablets compared with normal renal function, in male and female participants aged 18 to 79 years.

Conditions

  • Renal Impairment

Interventions

  • tolebrutinibDrug

    Pharmaceutical form: Film-coated tablets Route of administration: oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assessment of PK parameters Tolebrutinib: AUCTime frame: From Day 1 to Day 4
  2. Assessment of PK parameters M2: AUCTime frame: From Day 1 to Day 4

Locations

4 sites in 2 countries. Site status is shown where the registry gives one.

  • Clinical Pharmacology of Miami Site Number : 8400002

    Miami, Florida

  • Nucleus Network Site Number : 8400001

    Saint Paul, Minnesota

  • Volunteer Research Group-NOCCR Site Number : 8400003

    Knoxville, Tennessee

  • Investigational Site Number : 2760001

    Kiel, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.